Dr Lynn McCallum

Dr Lynn McCallum

Associate Professor of Haematology (Education)

School of Biomedical Sciences (Faculty of Health)

Dr Lynn McCallum can be contacted through arrangement with our Press Office, to speak to the media on these areas of expertise.
  • Haematology
  • Leukaemia
  • Prostate cancer
  • Cell signalling
  • Stem cell renewal


Associate Professor in Haematology (Education)
Programme Lead Healthcare Sciences

Programme Lead Applied Biomedical Sciences
Programme Lead Clinical Physiology


PhD University of Edinburgh
BSc (Hons) Queen's University Belfast
PGCAP Plymouth University 2012

Professional membership

American Society for Hematology
British Society for Haematology
International CCN Society
Fellow of the Higher Education Academy

Roles on external bodies

South West Lead Scientist Network representative for Plymouth University

Member of Association for Clinical Physiology Education



Teaching interests



Stem cell signalling

Targeted therapeutics

Professional practice

Staff serving as external examiners

External Examiner Bradford University, BSc Hons Healthcare Science (2017-2021)

External Examiner University of Ulster, MSc Biomedical Science (2021-2025)



Research interests

Investigation of CCN matricellular proteins in normal and malignant haematopoesis and solid tumour metastasis to bone. CCN proteins modulate stem cell signalling pathways including that of transforming growth factor beta, bone morphogenic protein, Notch and Wnt-beta-catenin. Abberations in CCN expression have been associated with a number of haematological malignancies including leukaemia and also in prostate cancer. CCN overexpression and knockdown systems have been created to identify the associated signalling pathways involved in tumourigenesis, advanced and resistant disease using gene array profiling. Identification of novel targeting strategies directed toward CCN associated stem cell signalling will allow development of novel therapeutics to more effectively target cancer.

Investigation of bioactive compounds from pharmaceutical plant species for use as novel agents in cancer. Research supported by European Regional Development Fund (ERDF). Extracts from pharmaceutical plant species will be tested on cancer cells lines from haematological and solid tumour derived cancer cell lines to establish clinical benefit. Extracts will be further fractionated to identify chemical species with bioactivity.

Self-funded PhD, ResM students or sponsored visiting specialists will be considered on an individual basis. Please contact me directly lynn.mccallum@plymouth.ac.uk

Research degrees awarded to supervised students

Sukanya Suresh PhD (QUB, 2011)

Afak Zaidi PhD (UoP, 2019)

Grants & contracts

Research and Innovation, Plymouth University R&I (2012, £37,250). Seedcorn investment to investigate ‘Targeting Prostate Cancer Progression’.

British Society for Haematology (2010, £6900). Start-up grant ‘Profiling CCN expression in Haematological malignancy’




Key publications

Key publications are highlighted

Rihan HZ, Aljafer N, Jbara M, McCallum L, Lengger S & Fuller MP (2022) 'The Impact of LED Lighting Spectra in a Plant Factory on the Growth, Physiological Traits and Essential Oil Content of Lemon Balm (Melissa officinalis)' Plants 11, (3) , DOI Open access
Zaidi A, Dresman S, Charoltte B, Rule S & McCallum LMR (2018) 'Molecular signatures for CCN1, p21 and p27 in progressive mantle cell lymphoma' Journal of Cell Communication and Signaling Author Site Publisher Site , DOI Open access
Suresh S, McCallum L, Crawford LJ, Lu WH, Sharpe DJ & Irvine AE (2013) 'The matricellular protein CCN3 regulates NOTCH1 signalling in chronic myeloid leukaemia' The Journal of Pathology 231, (3) 378-387 , DOI
Yakkundi A, McCallum L, O'Kane A, Dyer H, Worthington J, McKeen HD, McClements L, Elliott C, McCarthy HO & Hirst DG (2013) 'The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway' PLoS One 8, (2) Author Site , DOI
Burt C, Roddari J, Mindos T, Furtado M, Rule S & McCallum L (2013) 'CCN1 modulates cell growth in aggressive mantle cell lymphoma' BRITISH JOURNAL OF HAEMATOLOGY 161, 44-44
McCallum L, Lu W, Price S, Lazar N, Perbal B & Irvine AE (2011) 'CCN3 suppresses mitogenic signalling and reinstates growth control mechanisms in Chronic Myeloid Leukaemia' Journal of Cell Communication and Signaling 6, (1) 27-35 , DOI
Suresh S, McCallum L, Lu W, Lazar N, Perbal B & Irvine AE (2011) 'MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML' Journal of Cell Communication and Signaling 5, (3) 183-191 , DOI
Valentine A, O'Rourke M, Yakkundi A, Worthington J, Hookham M, Bicknell R, McCarthy HO, McClelland K, McCallum L & Dyer H (2011) 'FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism' Clin Cancer Res 17, (5) 1044-1056 Author Site , DOI
McCallum L, Bell D, Sturgess I & Lawrence K (2010) 'National ambulatory emergency care survey: Current level of adoption and considerations for the future' Clinical Medicine 10, (6) 555-559 , DOI
McCallum L, Lu W, Price S, Lazar N, Perbal B & Irvine AE (2009) 'CCN3: a key growth regulator in Chronic Myeloid Leukaemia' Journal of Cell Communication and Signaling 3, (2) 115-124 , DOI
Lu W, McCallum L & Irvine AE (2009) 'A rapid and sensitive method for measuring cell adhesion' Journal of Cell Communication and Signaling 3, (2) 147-149 , DOI
Crawford LJ, Windrum P, Magill L, Melo JV, McCallum L, McMullin MF, Ovaa H, Walker B & Irvine AE (2009) 'Proteasome proteolytic profile is linked to Bcr-Abl expression' Experimental Hematology 37, (3) 357-366 , DOI
McCallum L & Irvine AE (2008) 'CCN3 – A key regulator of the hematopoietic compartment' Blood Reviews 23, (2) 79-85 , DOI
McCallum L, Price S, Planque N, Perbal B, Pierce A, Whetton AD & Irvine AE (2006) 'A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation' Blood 108, (5) 1716-1723 , DOI
McCallum L & Irvine AE (2010) 'CCN3: A NOVel Growth Factor in Leukaemia' CCN Proteins in Health and Disease Springer Netherlands 213-221 , DOI
Conference Papers
McCallum L, Lu W, Price S, Suresh S, Lazar N, Perbal B & Irvine S (2011) 'CCN3 counteracts malignant features in chronic myeloid leukaemia' 14-14
Lu W, McCallum LMR, Price S, Planque N, Perbal B, Whettont AD & Irvine AE (2007) 'CCN3 reduces the clonogenic potential of BCR-ABL plus cells' 26-26
Mccallum LMR, Lu W, Price S, Planque N, Perbal B, Pierce A, Whetton AD & Irvine AE (2006) 'CCN3 expression reduces the clonogenic potential and growth of BCR-ABL plus cells' 13-14
McCallum LMR, Lu W, Price S, Planque N, Perbal B, Pierce A, Whetton A & Irvine AE (2005) 'BCR-ABL decreases the expression of CCN3 leading to increased clonogenic potential and cell growth' 354A-354A
Presentations and posters
Zaidi A, Mindos T, Hutchinson C, Rule S & McCallum L Zaidi A, Mindos T, Hutchinson C, Rule S & McCallum L 'Dysregulation of CCN1 expression in conjunction with increased expression of p21(CIP1) and p27(KIP1) implicated in mantle cell lymphoma progression' Author Site , DOI


Conferences organised

South West Lead Scientist hosting Healthcare Science Conference, 1st July 2019, UWE Frenchay Campus. 


International CCN Society: http://ccnsociety.com/index.html

British Society for Haematology: http://www.b-s-h.org.uk/

Society for Endocrinology: http://www.endocrinology.org